TC Biopharm Stock Set to Reverse Split on Monday, February 10th (NASDAQ:TCBP)

TC Biopharm (Holdings) Plc (NASDAQ:TCBP)’s stock is going to reverse split on the morning of Monday, February 10th. The 1-20 reverse split was announced on Wednesday, February 5th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, February 7th.

TC Biopharm Trading Down 30.1 %

NASDAQ:TCBP opened at $0.25 on Thursday. The business’s 50-day simple moving average is $0.43 and its 200-day simple moving average is $2.40. TC Biopharm has a fifty-two week low of $0.21 and a fifty-two week high of $26.16.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their price target on shares of TC Biopharm from $5.60 to $2.40 and set a “buy” rating for the company in a report on Friday, December 6th.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.